#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review
NEW ORLEANS — Following up on two subsets presented Saturday, Eli Lilly’s Loxo Oncology fleshed out the data on its non-covalent BTK inhibitor pirtobrutinib in patients with mantle cell lymphomas as an FDA decision looms on whether the daily pill can enter a field covered by three BTK rivals.
Loxo reported that 57.8% of MCL patients responded to pirtobrutinib. That comes from a group of 90 patients in the Phase I/II BRUIN trial who’d previously received a covalent BTK inhibitor. Eighteen patients (20%) had a complete response and 34 patients (37.8%) had a partial response. Stable disease was reported in 14 patients (15.6%).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
